Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from LifeTech Scientific Corporation ( (HK:1302) ).
LifeTech Scientific Corporation has announced the current composition of its board of directors, detailing five executive directors, one non-executive director and two independent non-executive directors, led by Chairman and Chief Executive Officer Xie Yuehui. The company also confirmed the structure of its three key board committees—Audit, Remuneration and Nomination—specifying the directors chairing and serving on each, underscoring its emphasis on corporate governance and regulatory compliance for stakeholders.
The most recent analyst rating on (HK:1302) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.
More about LifeTech Scientific Corporation
LifeTech Scientific Corporation is a medical device company listed in Hong Kong, focused on developing, manufacturing and marketing cardiovascular and peripheral vascular intervention devices. The company operates with a board composed of executive, non-executive and independent non-executive directors, reflecting a governance structure designed to meet regulatory and market expectations for listed healthcare technology firms.
Average Trading Volume: 32,494,192
Technical Sentiment Signal: Sell
Current Market Cap: HK$7.77B
For detailed information about 1302 stock, go to TipRanks’ Stock Analysis page.